Dr Rangan ChatterjeeFat Cell Scientist: 99% People Lose Weight & Stop Disease Faster With This Insulin Trick
Dr. Rangan Chatterjee and Dr Ben Bikman on insulin resistance explained, why it spreads disease, and reversal strategies.
In this episode of Dr Rangan Chatterjee, featuring Dr. Rangan Chatterjee and Dr Ben Bikman, Fat Cell Scientist: 99% People Lose Weight & Stop Disease Faster With This Insulin Trick explores insulin resistance explained, why it spreads disease, and reversal strategies Insulin resistance is defined as both reduced cellular response to insulin and chronically elevated insulin levels (hyperinsulinemia), which together disrupt metabolism across many organs.
At a glance
WHAT IT’S REALLY ABOUT
Insulin resistance explained, why it spreads disease, and reversal strategies
- Insulin resistance is defined as both reduced cellular response to insulin and chronically elevated insulin levels (hyperinsulinemia), which together disrupt metabolism across many organs.
- Population data suggest metabolic dysfunction is widespread globally, with ethnic differences in diabetes risk partly explained by fat-cell size and personal fat-storage capacity rather than body weight alone.
- Fasting glucose often stays normal for years while insulin rises, so a glucose-centric medical model can miss early disease and sometimes worsens outcomes by treating high glucose with therapies that increase insulin further.
- A “low-insulin lifestyle” emphasizes reducing refined sugars and starches, improving meal timing and fasting tolerance, and shrinking fat cells—often producing relatively rapid improvements in insulin sensitivity.
- Tools like CGMs (for glucose dynamics) and metabolic/ketone tracking can drive behavior change, while ketones—endogenous or supplemental—may have performance, brain, and metabolic benefits beyond simple fat loss.
IDEAS WORTH REMEMBERING
5 ideasInsulin resistance is not just “cells ignore insulin”—it also means insulin is chronically high.
Bikman frames insulin resistance as a paired state: impaired insulin signaling plus hyperinsulinemia, and this combination helps explain why one problem can manifest as obesity, fatty liver, PCOS, cardiovascular disease, and cognitive decline.
Metabolic health is best viewed through insulin, not just glucose.
Many people can have normal fasting glucose while insulin is elevated for years, so relying on glucose alone delays detection and misses the earlier, more actionable stage of dysfunction.
Body fat ‘amount’ is less predictive than fat-cell size and storage capacity.
He argues metabolic harm is driven more by hypertrophic (overstuffed) fat cells that become insulin resistant and inflammatory, versus having more numerous, smaller, insulin-sensitive fat cells.
Ethnicity can shift diabetes risk at the same BMI via a lower ‘personal fat threshold.’
South/East Asian (and some Hispanic) populations may reach harmful fat-cell hypertrophy sooner because they are less prone to create new fat cells, raising risk of fatty liver and insulin resistance at lower body weights.
A CGM is useful even if insulin is the main target—because glucose dynamics reveal insulin dysregulation.
A single fasting glucose test can look “fine,” while CGM patterns (high peaks, slow return to baseline, rebound lows) can indicate excessive insulin responses and impaired metabolic flexibility.
WORDS WORTH SAVING
5 quotesInsulin resistance is a two-part problem... The first part... is the idea that the hormone insulin isn't working as well as it used to... But the second part... is that blood insulin levels are elevated. So that's a condition called hyperinsulinemia.
— Dr Ben Bikman
Metabolic health is best defined as looking at the degree of insulin resistance, and insulin is the master metabolic hormone. It is the one hormone to rule all others.
— Dr Ben Bikman
Someone listening may be thinking, "Yeah, but Ben, you were asked about insulin resistance." What we call the metabolic syndrome used to be called the insulin resistance syndrome... this suggests that eighty-eight percent of US adults have some problem arising from insulin resistance.
— Dr Ben Bikman
Our failure to have a paradigm that at least encompasses insulin not only leads us to detect the problems too late, but to treat them not only poorly, but even in a way that can result in greater harm to the patient. Our strategy should be measure insulin and do what we can to bring the insulin down.
— Dr Ben Bikman
If insulin is elevated, the body is sugar burning. If insulin is low, the body is fat burning.
— Dr Ben Bikman
QUESTIONS ANSWERED IN THIS EPISODE
5 questionsIf hyperinsulinemia is central, what fasting insulin range do you consider “optimal,” and how should it be interpreted alongside triglycerides/HDL and HbA1c?
Insulin resistance is defined as both reduced cellular response to insulin and chronically elevated insulin levels (hyperinsulinemia), which together disrupt metabolism across many organs.
What’s your practical decision tree for someone who can’t access fasting insulin testing—how would you use waist circumference, blood pressure, lipids, skin signs (tags/acanthosis), and CGM data together?
Population data suggest metabolic dysfunction is widespread globally, with ethnic differences in diabetes risk partly explained by fat-cell size and personal fat-storage capacity rather than body weight alone.
How strong is the evidence that raising insulin pharmacologically in type 2 diabetes increases cardiovascular mortality—does it depend on drug class (e.g., insulin, sulfonylureas) and patient phenotype?
Fasting glucose often stays normal for years while insulin rises, so a glucose-centric medical model can miss early disease and sometimes worsens outcomes by treating high glucose with therapies that increase insulin further.
For South Asian patients specifically, what early warning markers (fatty liver, triglycerides, waist-to-height ratio, etc.) should trigger aggressive insulin-lowering interventions even at ‘normal’ BMI?
A “low-insulin lifestyle” emphasizes reducing refined sugars and starches, improving meal timing and fasting tolerance, and shrinking fat cells—often producing relatively rapid improvements in insulin sensitivity.
You emphasized ‘smart carbs’ rather than blanket low-carb—what are your top carbohydrate choices and cutoff points (grams/day or glycemic targets) for different goals (weight loss vs PCOS vs prediabetes)?
Tools like CGMs (for glucose dynamics) and metabolic/ketone tracking can drive behavior change, while ketones—endogenous or supplemental—may have performance, brain, and metabolic benefits beyond simple fat loss.
Chapter Breakdown
Insulin resistance explained: the two-part “villain” (resistance + high insulin)
Ben Bikman defines insulin resistance as a two-part condition: cells respond less effectively to insulin, and circulating insulin levels rise (hyperinsulinemia). He argues this explains why insulin resistance can drive many seemingly unrelated diseases across the body.
Why the terms don’t land: insulin seen as a drug, not a hormone
Chatterjee and Bikman discuss why the public often misunderstands insulin resistance and metabolic health. Insulin is commonly associated with diabetes treatment rather than a foundational hormone shaping energy use and long-term disease risk.
How big is the problem? Metabolic syndrome as a proxy for insulin resistance
Bikman describes the scale of metabolic dysfunction using U.S. data on metabolic syndrome and connects it to insulin resistance. He emphasizes this is a global issue, not confined to countries with high obesity rates.
Two origins of insulin resistance: “fast” (diet-driven) vs “slow” (fat-cell-size driven)
Bikman separates insulin resistance into a rapidly inducible form driven by chronically high insulin from frequent refined carbs, and a slower form tied to fat-cell hypertrophy. This framework helps explain different risk profiles across populations.
Ethnicity, fat-cell biology, and the “personal fat threshold”
Using Chatterjee (South Asian) and Bikman (Caucasian ancestry) as examples, they explore why equal weight gain can carry different metabolic risks. Bikman introduces the “personal fat threshold” and genetic influences on fat-cell creation vs enlargement.
Evolutionary lens: climate, vitamin D, and why fat-storage strategies differ
Bikman offers a hypothesis connecting ancestral geography, sunlight exposure, and insulation needs to fat storage patterns. They discuss how traits that may have been adaptive historically can become problematic in today’s food environment.
Why doctors miss it: glucose-first medicine vs earlier insulin signals
They argue insulin resistance is often undetected because clinical care focuses on glucose, a later marker. Bikman explains the historical and technical reasons for glucose dominance and why insulin measurement would catch risk earlier and change treatment.
Treating type 2 diabetes: lowering glucose by raising insulin can backfire
Bikman criticizes approaches that push insulin higher to reduce glucose without addressing hyperinsulinemia. He contrasts this with lifestyle strategies aimed at bringing insulin down, which should also lower glucose as a downstream effect.
Clues without bloodwork: skin signs that suggest high insulin
When fasting insulin tests aren’t available, Bikman notes two strong visible indicators of insulin resistance. These signs commonly appear where skin rubs and may improve as insulin resistance reverses.
A low-insulin lifestyle: smart carbs, protein/fat, and “mini-fasts”
Bikman lays out practical steps: reduce refined carbs, prioritize whole foods, and create longer gaps between meals to let insulin fall. He emphasizes this isn’t a war on all carbs, but a quality-and-pattern approach.
Metabolic flexibility and why fasting feels impossible for some people
They discuss how insulin governs fuel switching: high insulin keeps the body in sugar-burning mode, while low insulin allows fat-burning and ketone production. People who can’t transition easily may feel intense hunger despite having ample stored body fat.
Women, menstrual cycle phases, and fasting tolerance (follicular vs luteal)
Bikman explains sex-based differences in fasting and insulin sensitivity across the menstrual cycle. Progesterone in the luteal phase can increase hunger and insulin resistance, while the follicular phase often supports easier fasting and greater fat use.
Tools for behavior change: CGMs and breath-based fuel trackers (Lumen)
They reconcile “glucose is late” with the usefulness of CGMs by distinguishing fasting glucose snapshots from dynamic glucose responses. Real-time feedback helps people self-motivate, identify spikes, and adjust meal timing and composition.
Ketones: proof of fat burning, brain fuel, and exogenous ketone use (benefits + paradox)
Bikman argues ketones are a normal, beneficial signal of fat burning and a major brain fuel—especially relevant to infants and brain health. They discuss exogenous ketones for performance, cognition, and metabolic support, including the “high insulin + high ketones” paradox and why it may still be beneficial.
Personalization and wrap-up: biomarkers, lifestyle context, and one change to start tomorrow
They emphasize there are multiple routes to improved metabolic health, and outcomes should be judged by biomarkers and sustainability. Bikman’s closing advice: have a purpose beyond weight loss, and change breakfast immediately as a low-friction starting lever.
EVERY SPOKEN WORD
Install uListen for AI-powered chat & search across the full episode — Get Full Transcript
Get more out of YouTube videos.
High quality summaries for YouTube videos. Accurate transcripts to search & find moments. Powered by ChatGPT & Claude AI.
Add to Chrome